SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 13, 2009--
Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the
company’s executive vice president and chief financial officer, will
present at Lazard’s 6th Annual Healthcare Conference at 11:00
a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York.
Mr. Karbe will discuss the company’s corporate strategy, financial
outlook and development pipeline.
The event will be webcast and may be accessed in the Event Calendar page
under Investors at http://www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis’ broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech,
Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For
more information, please visit the company’s web site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Investor Contacts:
Charles
Butler, 650-837-7277
Vice President,
Investor
Relations
and Corporate Communications
cbutler@exelixis.com
or
DeDe
Sheel, 650-837-8231
Associate Director,
Investor
Relations
dsheel@exelixis.com
